Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7447)	2/9/1999 9:19:00 AM
From: LLCF	Read Replies (1) \| Respond to of 8116

More insider buying in this pig... are these guys gluttons for punishment or what??? DAK

To: Jim Oravetz who wrote (7447)	4/9/1999 12:45:00 PM
From: Jim Oravetz	Respond to of 8116

DiagnoCure Develops Test To Detect Prostrate Cancer Spread Dow Jones Newswires QUEBEC CITY -- DiagnoCure Inc. (M.CUR) said it has developed a test for the early detection of circulating prostate cancer tumor cells from which cancer can metastasize, or spread. {Error in web pg?)s release, the company said the test, still in the experimental stage, will be made available to cancer research centers for clinical testing. It said the test, which will be marketed under the name DiagnoGene, detects an RNA tumor marker present in prostate cancer. It has filed a patent application for the marker, it said. DiagnoCure is a biopharmaceutical company. This may take a while to come into a product. Not sure how it may compete with CYTO's detection methods. Jim